Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Experts Explore Ways to Strengthen Protection from Viral Contamination

This article was originally published in The Gold Sheet

Executive Summary

Adding viral barriers and testing can prevent shutdowns like Genzyme's - or create ones like Glaxo's. What is the right balance? WCBP symposium explores relative merits of treatment barriers and testing. The testing FDA's vaccines office recommends. The combination approach. FDA's advice for winning approval to add treatment barriers.

You may also be interested in...

MIT Consortium Shares Secrets to Prevent Viral Contaminations

MIT provides way for biopharma to share learnings from adventitious agent contamination incidents anonymously. The goal is to better identify, correct and prevent viral and other contaminations.

Vaccines Face Unknown Contamination Risks, But Need Well-Defined Testing

The discovery of adventitious porcine virus in Merck's RotaTeq and GlaxoSmithKline's Rotarix is setting off a scramble among vaccine manufacturers and FDA to come up with validated procedures to detect and deal with such undesirable agents

Vaccines With Live Attenuated Virus May Face Greater Post-Marketing, Manufacturing Requirements

FDA advisory committee on May 7 will consider Porcine circovirus 1 found in GlaxoSmithKline's Rotarix as well as "adventitious" material found in two other vaccines.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts